UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF

NCT06860334 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

378

Enrollment

OTHER

Sponsor class

Conditions

Crimean-Congo Hemorrhagic Fever

Interventions

DRUG: Favipiravir
DRUG: Ribavin
OTHER: Optimised Standard of Care

Sponsor

Liverpool School of Tropical Medicine